Main > > >HEAD & NECK CANCER. *

---

Onco.>PhotoImmunoTherapy. CetuxiMAb Saratolacan Na.
(Locally Advanced or Recurrent UnResec
table)
JP Approval Date: 2020. 09.25.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2021. 02.22.




Onco.>RadioTherapy>BrachyTherapy>Low Ra-
te Dose (LRD) BrachyTherapy.
>Indications Potential>
>atypical meningioma
>non-small-cell lung cancer
>ocular melanoma
>Indications Used>
>colorectal cancer
>gynecological cancer
>head and neck cancer
>pancreatic cancer
>soft tissue sarcomas
USA Approval Date: 2014. 08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.25.




Onco.>RadioTherapy>Oral Positioning Stents.
EU CE Mark Date : ?
USA 510(k) Clearance Date: 2019. 04.11.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.25.




Recurrent Human Papilloma Virus (HPV)-related Head and Neck (Oropharyngeal) Cancer. Identification Blood Test.
USA Provision to Cancer Centers of Excellence Date: 2020. 02.05.
(*) Company : Naveris Inc.
TradeMark: NavDx
Web-Site :
naveris.com/patientsphysicians/navdx
UpDate: 2020. 02.09.




Squamous Cell Carcinoma. Treat.: Doce-
Taxel Inj.+Cisplatin+Fluorouracil
USA Initial Approval Year: 1996.
(*) Company : sanofi-aventis U.S. LLC
TradeMark: Taxotere
UpDate: 2018. 10.02.




Squamous Cell Carcinoma. Treat.: Doce-
Taxel Inj. Alcohol-Free+Cisplatin+Fluo- rouracil.
USA Approval Date: 2015. 12.28.
USA Launch Date: 2016. 02.02.
(*) Company; Patents; PR Web-Site &
TradeMark Available on Request.
UpDate: 2018. 10.29.




Squamous Cell Carcinoma. Treat.: Hydro-
xyUrea+ChemoRadiation
(Locally Advanced)
USA Initial Approval Year: 1967.
(*) Company : Bristol Myers Squibb
Patent : Expired
TradeMark: Hydrea
UpDate: 2018. 10.02.




Squamous Cell Carcinoma. Treat.: Nivo-
luMAb.
[METASTATIC OR RECURRENT (R)]
2nd Line Therapy After Pt ChemoTherapy.
CA Approval Date: 2017. 05.17.
EU Approval Date: 2017. 04.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.01.




Squamous Cell Carcinoma. Treat.: Pem-
brulizuMAb.
[METASTATIC OR RECURRENT (R)]
1st Line Treat. Tumors Express PD-L1
[Combined Positive Score (CPS)]>1
>Companion Diagnostics>
>USA Approval Date: 2019. 06.11.
CA Approval Date : 2020. 10.15.
EU Approval Date : 2019. 11.20.
JP Approval Date : 2019. 12.20.
USA Approval Date: 2019. 06.11.
(*) Companies; TradeMarks; USA Patent
APP.; USA Patents & Web-Sites
Available on Request.
UpDate: 2021. 02.18.




Squamous Cell Carcinoma. Treat.: Pem-
brulizuMAb.
[METASTATIC OR RECURRENT (R)]
2nd Line Treat.>Pt ChemoTherapy
USA Approval Date: 2016. 08.08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.01.




Squamous Cell Carcinoma. Treat.: Pem-
brulizuMAb.+Pt+FluoroUracil (FU)
[METASTATIC OR RECURRENT (R)]
Regardless of PD-L1 Expression.
EU Approval Date : 2019. 11.20.
JP Approval Date : 2019. 12.20.
USA Approval Date: 2019. 06.11.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.01.




Treat.: CetuxiMAb Inj.+Pt based Chemo with 5-Fluorouracil.
(RECURRENT or METASTATIC)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.02.




Treat.: CetuxiMAb Inj.+RadioTherapy.
(METASTATIC)
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.02.




Treat.: Post-Operative Radiation.
radiation port includes a substantial portion of the parotid glands.
Xerostomia Reduction: Amifostine for Inj.
Xerostomia: Dry Mouth/Sjoegrens
USA Launch Date: 2016. 09.26.
(*) Company/Licensee: Cumberland
Pharma
Company/Licensor: Clinigen Group
Patent : Expired.
TradeMark : Ethyol
Web-Site :
www.ethyol.com/usa/
UpDate: 2018. 10.02.



>HEAD & NECK CANCER. *'s products
This section has no products